IPCALABPharmaceuticals
Ipca Laboratories Ltd — Cash Flow Statement
₹1601.20
+1.02%
Ipca Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Changes In Cash | 168.84 Cr | -899.69 Cr | 588.05 Cr | 427.80 Cr | — |
| Financing Cash Flow | -282.98 Cr | -552.55 Cr | 507.24 Cr | 426.78 Cr | — |
| Interest Paid Cff | -74.35 Cr | -134.25 Cr | -41.48 Cr | -6.18 Cr | — |
| Cash Dividends Paid | -101.48 Cr | -50.74 Cr | -101.48 Cr | -101.48 Cr | — |
| Net Issuance Payments Of Debt | -93.25 Cr | -356.88 Cr | 657.71 Cr | 540.32 Cr | — |
| Net Short Term Debt Issuance | -63.94 Cr | -303.83 Cr | 294.27 Cr | 193.34 Cr | — |
| Net Long Term Debt Issuance | -29.31 Cr | -53.05 Cr | 363.44 Cr | 346.98 Cr | — |
| Long Term Debt Payments | -247.68 Cr | -176.76 Cr | -28.25 Cr | -66.72 Cr | — |
| Long Term Debt Issuance | 218.37 Cr | 123.71 Cr | 391.69 Cr | 413.70 Cr | — |
| Investing Cash Flow | -869.50 Cr | -1.29K Cr | -725.00 Cr | -855.05 Cr | — |
| Net Other Investing Changes | -97.14 Cr | 509.96 Cr | -229.34 Cr | -155.98 Cr | — |
| Interest Received Cfi | 24.00 Cr | 80.88 Cr | 54.23 Cr | 33.03 Cr | — |
| Net Investment Purchase And Sale | -6.25 Cr | 64.78 Cr | 0.00 | -25.04 Cr | — |
| Sale Of Investment | 0.00 | 64.78 Cr | 0.00 | — | — |
| Purchase Of Investment | -6.25 Cr | 0.00 | 0.00 | -25.04 Cr | — |
| Net Business Purchase And Sale | -27.20 Cr | -1.57K Cr | -55.93 Cr | -240.83 Cr | — |
| Purchase Of Business | -27.20 Cr | -1.57K Cr | -55.93 Cr | -240.83 Cr | — |
| Provisionand Write Offof Assets | 121.57 Cr | 136.89 Cr | -0.28 Cr | 0.36 Cr | — |
| Depreciation And Amortization | 397.82 Cr | 357.24 Cr | 261.56 Cr | 232.42 Cr | — |
| Depreciation | 377.85 Cr | 333.08 Cr | 261.56 Cr | 212.20 Cr | — |
| Gain Loss On Investment Securities | 4.03 Cr | -72.55 Cr | 1.38 Cr | -2.78 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 10.16 Cr | -7.20 Cr | 18.70 Cr | -9.94 Cr | — |
| Gain Loss On Sale Of PPE | -0.74 Cr | -3.49 Cr | -13.21 Cr | 11.39 Cr | — |
| Net Income From Continuing Operations | 1.13K Cr | 842.67 Cr | 745.29 Cr | 1.14K Cr | — |
| Free Cash Flow | 545.75 Cr | 533.36 Cr | 311.34 Cr | 377.12 Cr | — |
| Repayment Of Debt | -247.68 Cr | -176.76 Cr | -28.25 Cr | -66.72 Cr | — |
| Issuance Of Debt | 218.37 Cr | 123.71 Cr | 391.69 Cr | 413.70 Cr | — |
| Capital Expenditure | -775.57 Cr | -411.29 Cr | -494.47 Cr | -478.95 Cr | — |
| End Cash Position | 924.63 Cr | 755.79 Cr | 1.58K Cr | 990.93 Cr | — |
| Beginning Cash Position | 755.79 Cr | 1.58K Cr | 990.93 Cr | 559.01 Cr | — |
| Net PPE Purchase And Sale | -770.19 Cr | -401.98 Cr | -458.32 Cr | -476.11 Cr | — |
| Sale Of PPE | 5.33 Cr | 8.62 Cr | 36.15 Cr | 2.84 Cr | — |
| Purchase Of PPE | -775.52 Cr | -410.60 Cr | -494.47 Cr | -478.95 Cr | — |
| Capital Expenditure Reported | -0.05 Cr | -0.69 Cr | 0.00 | — | — |
| Operating Cash Flow | 1.32K Cr | 944.65 Cr | 805.81 Cr | 856.07 Cr | — |
| Taxes Refund Paid | -361.25 Cr | -296.30 Cr | -223.65 Cr | -202.04 Cr | — |
| Change In Working Capital | -176.46 Cr | -91.59 Cr | 48.99 Cr | -272.72 Cr | — |
| Change In Other Current Liabilities | -78.69 Cr | 81.43 Cr | -12.79 Cr | 161.58 Cr | — |
| Change In Other Current Assets | 116.39 Cr | -14.95 Cr | 42.23 Cr | 1.44 Cr | — |
| Change In Payable | 72.66 Cr | 21.49 Cr | -32.40 Cr | -109.69 Cr | — |
| Change In Inventory | -91.56 Cr | -94.70 Cr | 114.60 Cr | -249.15 Cr | — |
| Change In Receivables | -217.67 Cr | -75.80 Cr | -68.10 Cr | -80.24 Cr | — |
| Other Non Cash Items | 51.49 Cr | 75.91 Cr | -33.81 Cr | -33.97 Cr | — |
| Stock Based Compensation | 2.06 Cr | 3.06 Cr | 0.00 | — | — |
| Amortization Cash Flow | 19.97 Cr | 24.16 Cr | 25.37 Cr | 20.22 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | 76.50 Cr | — | 4.12 Cr | — |
| Net Other Financing Charges | — | — | -0.20 Cr | — | — |
| Issuance Of Capital Stock | — | — | — | 0.00 | 35.81 Cr |
| Net Common Stock Issuance | — | — | — | 0.00 | 35.81 Cr |
| Common Stock Issuance | — | — | — | 0.00 | 35.81 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ipca Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.